Advancing Novel Covalent Therapies to the Clinic 

Covalent drug discovery entered a defining new phase where scientific validation was no longer the primary barrier; successful clinical translation now takes center stage. As the field moved beyond first-generation targeted covalent inhibitors, researchers are advancing more sophisticated approached to covalent inhibitor design, unlocked new opportunities for covalent drug development across previously inaccessible targets.

Once limited by concerns around off-target toxicity, covalent approaches were unlocking undruggable targets and expanding beyond oncology into new therapeutic areas. As next-generation covalent warheads, chemoproteomics, and AI-driven design accelerated innovation, the key challenge was clear: how to translate covalent candidates into safe, effective clinical therapies.

The 4th Covalent Drug Discovery & Development Summit is the only industry forum dedicated to advancing covalent therapeutics end-to-end, from early covalent screening and hit discovery through covalent drug development, IND-enabling studies, and early clinical development.

Uniting experts from Bristol Myers Squibb, Novartis, Pfizer, Biogen, Nexo Therapeutics, and Frontier Medicines, this summit goes beyond high-level discussion to deliver data-driven case studies on covalent binding, target engagement assays, covalent kinetics, non-cysteine targeting, translational strategy, and clinical development.

80+ leaders Joined us in covalent drug discovery and development to:

• De-risk your pipeline with early clinical and translational learnings
• Overcome challenges in covalent selectivity, safety, target engagement, and PK/PD
• Explore advances in chemoproteomics, covalent screening, and novel warhead design
• Gain candid insights not found in publications

As more covalent drugs entered the clinic, it was time to turn promise into proof and accelerate the next generation of covalent therapeutics.